About EGRIFTA® (tesamorelin for injection)
What Is EGRIFTA®?
EGRIFTA® is an injectable prescription medicine to reduce the excess abdominal fat in HIV-infected patients with lipodystrophy. It is thought to work with your own body to produce natural growth hormone to reduce your excess abdominal fat.
- The impact and safety of EGRIFTA® on cardiovascular health has not been studied.
- EGRIFTA® is not indicated for weight loss management.
- It is not known whether taking EGRIFTA® helps improve compliance with anti-retroviral medications.
- It is not known if EGRIFTA® is safe and effective in children. EGRIFTA® is not recommended to be used in children.
Results With EGRIFTA®
In two separate clinical trials, at six months, EGRIFTA® reduced visceral adipose tissue by an average of 18% in the first trial, and by an average of 14% in the second. EGRIFTA® is not indicated for weight loss management.
Like HIV, HIV-related excess abdominal fat is a chronic condition. So, people who used EGRIFTA® continuously for 1 year maintained their results over this time period. People who stopped using EGRIFTA® after 6 months had VAT come back.
Some patients with HIV-related excess abdominal fat can feel distressed about the appearance of their abdomen. In clinical trials of EGRIFTA®, a greater percentage of people who took EGRIFTA® reported an improvement in the appearance of their abdomen than people who did not take EGRIFTA®.
Individual results may vary.